{{Rsnum
|rsid=6680578
|Gene=EVI5
|Chromosome=1
|position=92711321
|Orientation=plus
|GMAF=0.3558
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=EVI5
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 45.1 | 43.4 | 11.5
| HCB | 85.4 | 13.1 | 1.5
| JPT | 90.3 | 8.8 | 0.9
| YRI | 10.9 | 41.5 | 47.6
| ASW | 17.9 | 55.4 | 26.8
| CHB | 85.4 | 13.1 | 1.5
| CHD | 79.8 | 18.3 | 1.8
| GIH | 60.4 | 34.7 | 5.0
| LWK | 7.3 | 45.5 | 47.3
| MEX | 53.6 | 39.3 | 7.1
| MKK | 12.2 | 42.3 | 45.5
| TSI | 46.1 | 41.2 | 12.7
| HapMapRevision=28
}}[[rs6680578]] has been reported in a large study to be associated with [[multiple sclerosis]].

The risk allele (oriented to the dbSNP entry) is (T); the odds ratio associated with this allele is 1.11 (CI 1.04-1.17). {{PMID|17660530}}

{{PharmGKB
|RSID=rs6680578
|Name_s=
|Gene_s=EVI5
|Feature=
|Evidence=PubMed ID:17660530
|Annotation=In a replicated GWAS of U.K. and U.S. case/parent trios, this variant was shown to be associated with multiple sclerosis risk.
|Drugs=
|Drug Classes=
|Diseases=Multiple Sclerosis
|Curation Level=Curated
|PharmGKB Accession ID=PA162356170
}}

{{PMID Auto
|PMID=20087403
|Title=Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6680578
|overall_frequency_n=73
|overall_frequency_d=128
|overall_frequency=0.570312
|n_genomes=45
|n_genomes_annotated=0
|n_haplomes=63
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}